
Health Matters newsletter: When heat is the central paradigm
On rising temperatures and climate change, India's air quality, the need for geriatric care services, the landmark agreement on tackling future pandemics, and more
This is not old wine in new bottle, this is mulled wine you forgot to throw spices into, but that glass is frothing with all the overheating that is happening this summer. There is May to come, and if the heat is already that bad, one's brow rises up with beads of sweat at the mere contemplation. So this week, we are talking about the thing that every one is discussing furiously - heat, and that which is not as energetically debated - climate change.
On March 15, some States and cities in India experienced the first of severe heatwaves for the year 2025. This was 20 days earlier than the first severe heatwave in 2024, making it very clear that climate change is indeed upon us.
India's air quality way off WHO markers, Maria Neira, director of the Department of Environment, Climate Change and Health at the World Health Organization (WHO), said last week. She urged the Indian authorities to scale up existing programmes, particularly those aimed at reducing household air pollution caused by the use of biomass fuels for cooking. 'We need to consider programmes like providing access to LPG and subsidies, but of course, the effort has to be not only maintained but probably scaled up,' said Ms. Neira.
Staying on air pollution, here's a story about how people in an industrial town on the border of Assam and Meghalaya, battle respiratory issues, skin rashes, living as they do in world's most polluted town. Byrnihat's annual average PM2.5 concentration in 2024 was 128.2 micrograms per cubic meter, according to IQAir, over 25-times the level recommended by the WHO. PM2.5 refers to particulate matter measuring 2.5 microns or less in diameter that can be carried into the lungs, causing deadly diseases and cardiac problems. Residents referred to family members and neighbours 'breathing like a fish' thanks to all the pollution. Byrnihat's air quality remains poor through the year, government data indicates.
Here's a report on yet another Study that linked climate change with rising arsenic levels in rice, increasing cancer risks for Asians. According to the study, rising temperatures and CO2 levels could lead to a substantial increase in arsenic levels in rice, potentially causing tens of millions of cancer cases in Asian countries by 2050. Researchers from Columbia University, U.S., explained that an increase in temperatures above 2 degrees Celsius and rising levels of carbon dioxide could be causing changes in soil chemistry, favouring arsenic, which gets more easily absorbed into a rice grain. Contaminated soil and irrigated water while growing rice are known to increase inorganic arsenic in rice.
In the global south, in the south of the Indian subcontinent, heat is a very serious concern. K. Lakshmi and Geetha Srimathi record how the Rising humidity level in a coastal city makes things very uncomfortable for Chennai residents. Wet bulb temperature-induced discomfort is real, if you are living in a coastal city these days.
Meghna M. reports that Parents are worried about heat, even when putting children into summer camps while Serish Nanisetti writes that Telangana prepares for 'warming planet' with higher ex-gratia, district-wise heatwave plan. Already we learnt that Tamil Nadu had declared heat at a state disaster, thus facilitating rehabilitation and funding to address heat-related impacts on people.
Dr. Chandrakant Lahariya brings up the tail with a list of things to do: Beat the heat with people-centric responses, he says, introducing the concept of heat stress early on in the article.
This week we happened to have a couple of articles focusing on elder care. What with a demographic transition in place in the country, swinging more to the grey zone, it is important that healthcare managers and governments begin focussing on how to take care of the elderly. While Serena Josephine M. wrote on the The necessity for, and the challenges that lie in caring for India's elderly population, Shilpa Elizabeth added the community aspect to the equation of elder care.
Equitable access and affordable health care should be at the centre of most discussions in the subcontinent. The quality of public health care is a constant and must continue to be a constant source of concern for the government, which is in many places, the largest provider of healthcare to the people. Irfan Shakeer and Dr. Janane S. write about the importance of Making primary health visible, offering accessible and affordable health care.
Dr. Kinshuk Gupta's article A call to action: Haemophilia patients in India need timely diagnosis, affordable treatment again, addresses the same paradigm for an exclusive group of patients, one whose demands on the healthcare system is more regular. All the more of concern to India, which reportedly has the second-highest load of patients with hemophilia A in the world, and is the only developing country amongst the top five countries in the world.
In terms of sheer numbers, chronic kidney disease, likely caused by the epidemic of hypertension and diabetes is alarming. The urgent need to bridge gaps to make dialysis more accessible and affordable for patients. According to the Pradhan Mantri National Dialysis Program, which was rolled out in 2016 to provide free dialysis to the poor, about 2.2 lakh new patients with end-stage renal disease get added in India every year, resulting in an additional demand for 3.4 crore dialysis sessions. There are however, only 11,148 haemodialysis machines in the country.
Athira Elssa Johnson turns the spotlight on Newborn screening crucial for early detection of primary immunodeficiency. Globally, the WHO and other studies acknowledge over 430 distinct PI associated disorders, affecting an estimated six million people. Alarmingly, up to 90% of these cases remain undiagnosed.
The Hindu also paid tribute to a dear friend of the health sector, Dr. Mathew Samuel Kalarickal, widely acknowledged as the father of Indian angioplasty. He first introduced angioplasty in the country at Apollo Hospitals in Chennai, giving patients a convenient and less risky option to open heart surgery and a more effective option than drugs.
In other news, I write about a meta-analyses that recently proved Almonds rein in weight, cholesterol and hypertension in mild to moderate amounts if consistently ingested.
The Prime Minister Narandra Modi pitched for a fitter India, on the occasion of World Liver Day, and while you are at it, see if you can answer our quiz On liver health.
Meanwhile, in a significant development, WHO countries strike landmark agreement on tackling future pandemics after several rounds of discussions. 'At a time when multilateralism is under threat, WHO member states have joined together to say that we will defeat the next pandemic threat in the only way possible: by working together,' said New Zealand's former prime minister Helen Clark, co-chair of the Independent Panel for Pandemic Preparedness and Response. Do read The Hindu's editorial on the subject: Landmark agreement: On the draft WHO Pandemic Agreement.
There are a couple of contenders for this week's tailpiece segment. If a Dr. Dog enters the picture, is that a story we can ignore? Geetha Srimathi writes about the four legged teacher: At this Chennai school, 'Dr. Dog' helps children with special needs learn, communicate and build social skills. Saraswati Kendra uses animal-assisted therapy to help its students who have learning disabilities and autism, develop behavioural skills. Psychologists at the school say the pet is used as a bridge to encourage children to open up
Also, if you have asked, or wondered if twins are allergic to the same things, here is an answer. Breanne Hayes Haney in The Conversation: Are twins allergic to the same things? The short answer is 'Yes, they can be allergic to the same things, but not always'. Hit on the link to learn more.
As usual, we have a rich bunch of explainers this week:
Zubeda Hamid wonders Why health insurance premiums are so high in India in the In Focus podcast.
Dr. Ashok Chacko writes on Understanding irritable bowel syndrome and how to manage it.
In the All you need to know about: Bindu Shajan Prappadan writes on Gluten allergies, also check this on Blood pressure.
Dr. Abhijit Joshi answers a question many are asking: Doctor, will I ever run again? On life after a heart attack.
Dr. Nagarajan V. explains The role of vaccines in protecting communities from disease.
C. Maya lays out the context on Why ASHA workers are protesting in Kerala?
Dr. Arvind Radhakrishnan Demystifies the many causes behind syncope
A. Jaishree Gajaraj writes on the science behind 'miracle babies' born of uterine transplants
Niranjana P.S. tells you How your immune system reacts through anaphylactic shocks to protect you from the 'invaders'
If you have a few extra moments, also check out the following links:
Trials demonstrate safety of stem cell therapy for Parkinson's
Doctors urge vigilance amid rise in accidental ingestions among kids during summer vacations
Navaneeth Krishna V.: Tiny pacemaker ups the ante on device's abilities
Afshan Yasmeen: Soon all hospitals may have to share data on elective joint surgeries with Health Department
Govt bans the manufacture, sale of 35 fixed-dose combination drugs
—
For many more health stories, head to our health page and subscribe to the health newsletter here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
31 minutes ago
- Time of India
One cough too many: India's TB fight isn't quite there yet
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads MISSING CASES Tired of too many ads? Remove Ads NEW HOPE, OLD GAPS A CURE WITH ISSUES WHAT NEXT? One moment Anushka (name changed) was a college student. Then her world turned upside down. It started with a persistent cough and high fever. Despite popping meds, it wouldn't go away. Tests followed and then came the news that knocked the stuffing out of her—she had a fatal form of tuberculosis TB ). With scarred lungs, she gasped for each breath. The bacteria had killed her appetite, making her frail and bony. Her skin colour changed—to dark and then grew paler. At 20, her life expectancy dwindled to a few months.'I felt weak,' she recalls, 'and preferred to be alone.'Battling extensively drug-resistant tuberculosis or XDR-TB, a form of the disease in which drugs rarely worked, Anushka's only option was to be loaded each day with scores of tablets and injections. Those came with toxic side effects. For over four years, she moved between government and private hospitals, enduring cycles of failed came only when she was placed on a salvage regimen—the last option when all other interventions are exhausted—at a Médecins Sans Frontières (MSF) clinic in Govandi, Mumbai. The global humanitarian group offered Anushka a cocktail of bedaquiline , delamanid and imipenem injections, a set of very powerful meds often inaccessible to most Indians due to supply restrictions aimed at curbing drug who has now recovered, recounted her ordeal at MSF's TB Day event in Mumbai on May 12, speaking before an audience of doctors, a quiet smile breaking through years of pain. Her journey to recovery is rare, and alien to millions in India, which reflects a public health system still failing its most vulnerable. India now accounts for more than a quarter of all TB cases reported worldwide. In 2023, the country had 26% of the global TB burden, according to the World Health Organization (WHO). Bending the curve remains difficult despite multiple national can India improve?In 2018, when India pledged to eliminate TB by 2025, five years ahead of the set global target, the objective was clear. And progress has been made, too. Between 2015 and 2023, TB incidence (new and relapsed cases per 1 lakh population every year) fell by 18% and deaths by 24%, per is a sign in the right direction, but the number of cases are still astounding, especially when it comes to drug-resistant variants. 'India bears the highest burden of XDR-TB globally, with an estimated 110,000 new cases annually,' says Professor Anil Koul of the London School of Hygiene and Tropical Medicine. A key figure in TB drug research, Koul was part of a Johnson & Johnson team that developed bedaquiline, one of the most effective drugs against resistant TB notes that Covid-19 deepened the crisis, and underfunded research has stalled progress. Of the 27 drugs in clinical trials, none have reached Phase III. Bedaquiline remains the mainstay.A 100-day TB Elimination Challenge was launched by the government in December 2024 to amplify efforts to diagnose and treat TB at the village level, but experts aren't satisfied.'We are not on track,' says Dr Animesh Sinha, chronic care and infectious disease advisor, MSF. 'To meet the 2025 milestones of WHO's End TB strategy, India should achieve a 50% reduction in TB incidence rate and a 75% reduction in the total number of TB deaths compared with 2015.' Although numbers have fallen, the quantum has been woefully short of the target, as WHO numbers suggest.A PIB release dated March 24, 2025, says India's TB elimination targets for 2025 are an 80% reduction in incidence and a 90% reduction in deaths, compared with 2015.A key problem is underreporting emanating from under-diagnosis. India's notification rate (number of TB cases diagnosed and officially reported) has improved from 108 per 100,000 population in 2010 to 166 in 2023, yet many cases, especially in rural areas, go undetected.'In order to address the TB crisis, we have to find the missing cases,' says Sinha. Nonetheless, the 2025 goal helped push TB up the political agenda. Ni-kshay, a digital platform for notification and treatment monitoring, is improving reporting. But without proportionate investment in diagnostics, staffing and drug access, the pace of progress will be drug shortages have been reported, and India spent just 2.1% of the National Tuberculosis Elimination Programme budget on diagnostics till 2023-24, an IndiaSpend RTI revealed.'The 2025 target was always a stretch,' says Koul. 'But it did galvanise government machinery, leading to faster approvals for newer regimens like bedaquiline, speedier rollout across TB centres and more budgetary support, including for nutritional aid.'That said, TB continues to receive only a sliver of public health funding. But even so, he notes, there certainly is a positive trend in fighting back, considering the complexity of the disease and the socioeconomic factors shaping in an ET Morning Brief podcast in January, Dr Urvashi Singh, deputy director-general (TB), Ministry of Health and Family Welfare, said, 'The domestic budget for the national TB programme has increased over five times in the last 10 years.' India, she added, is the only high-burden country where 91% of the programme is backed by domestic detection is often the difference between quick recovery and years of suffering. Goa-based diagnostic device maker Molbio Diagnostics' Truenat, a portable molecular-testing platform, introduced in 2017, expanded diagnostic access, particularly in low-access regions. 'We supplied over 90 lakh testing kits last year and expect to provide 1.25 crore this year,' says Sriram Natarajan, CEO of Molbio, which is working with government and statelevel partners to rollout molecular testing.A Truenat test costs just Rs 640, a fraction of what imported diagnostics demand, says Natarajan. In public health, he argues, the real measure isn't price, but cost-effectiveness, especially when early detection can avert far greater globally approved diagnostics protocols remain out of reach in India. The WHO-recommended urine TBLAM test, used to diagnose TB in HIVpositive patients, is still unavailable in the country, despite successful validation studies in Mumbai in 2022. Registration barriers and lack of supply from manufacturers have led to lack of access, says Leena Menghaney, a public health lawyer based in Delhi. Supplyrelated issues could be because trials in India have yet to conclude, according to industry delays cost precious lives. Late detection risks high transmission rates and complications for patients. Dr Jennifer Furin, infectious diseases clinician, Harvard Medical School, says while Truenat is helpful and the diagnostic pipeline is robust, the outdated and slow systems for approving novel tools in India have a detrimental impact. Furin points to a critical gap: the lack of household-level prevention. Studies, including a 2023 trial published in TheLancet, show that modest nutritional support for families of TB patients can sharply reduce transmission. Another model, published in TheLancet this year, estimates that improving household nutrition alone could prevent nearly 5% of TB deaths by carrying the world's highest TB burden, regulatory reforms have been slow in India. Some gains have been made, but systemic delays continue to blunt the impact of new patients with drug-resistant TB, a new wave of treatment offers hope, but conditions apply. Regimens like a six-month, all-oral combination termed BPaLM— bedaquiline, pretomanid, linezolid and moxifloxacin—have been game-changers, replacing the gruelling 24-month regimens of daily injections and pills. 'These regimens are better tolerated and highly effective, with about 90% of people completing treatment successfully,' says clinicians welcome the government's push for shorter regimens, access remains limited—only 1,700 patients in India have received them, according to Dr Rupak Singla, head of the department of respiratory medicine, National Institute of Tuberculosis and Respiratory Diseases , Delhi, who spoke at the event in Mumbai. Adoption has lagged due to limited access to drug susceptibility testing for newer drugs, which is crucial for choosing an appropriate treatment BPaLM regimen can't be given in cases where more than one organ system is involved or in patients with severe extrapulmonary disease, 'both of which are common in India,' according to Dr Alpa Dalal, head of unit, Group of TB Hospitals, Sewri, Mumbai. BPaLM should not be prescribed for patients previously treated with bedaquiline, says Dalal, unless drug susceptibility to bedaquiline and linezolid is says even in extensive pulmonary TB, where studies have shown good outcomes with BPaLM, many clinicians are cautious. In longer regimens, patients with extensive lung involvement have had higher relapse rates, compared with patients with limited disease, she explains, and that concern carries over. A study published in OUP's research platform, Oxford Academic, in March 2025 shows that bedaquiline resistance among previously treated patients can reduce the drug's warn that such resistance could undercut its effectiveness in the long term if not addressed early. But Koul says, 'Bedaquiline has galvanised TB R&D. It will remain a core component of future regimens, unless we see a dramatic rise in resistance in clinical practice.'The economics of care create barriers too. Pricing is a big hurdle. Regimens with imipenem cost thousands of rupees per day. Anushka was treated free by MSF. Else each injection alone, she said, would cost Rs 2,499. Considering the socioeconomic realities of India, perhaps this is where the government could step approach to procurement is problematic too. The country selectively joins pooled procurement platforms like the Global Drug Facility, which could reduce costs. 'India has in the past refused to participate in this, unless they had an emergency,' says policy and procurement, TB is a profoundly social disease, shaped by stigma, poverty and undernutrition. Even the best drugs won't work if care doesn't reach those who need it most. Guidelines may improve and approvals may accelerate but until the system meets people where they are, too many will be left suffered for years before she got cured. Her strength wasn't just in surviving; it was in refusing to give up. 'Even in that condition, I completed my graduation and kept chasing my dreams,' she says. India's TB response must now rise to match that grit, with urgency, equity and compassion.


Deccan Herald
an hour ago
- Deccan Herald
Pregnant, undiagnosed, and at risk
Despite progress in reducing maternal deaths, too many Indian women still miss routine pregnancy tests. Lakshmi Sethuraman & Ritika Ramasuri offer a closer look at the silent barriers to diagnostics in maternal care


Time of India
an hour ago
- Time of India
Zero Type 1 diabetes cases by 2047 a revolutionary dream from Nagpur: CM
Nagpur: Chief minister Devendra Fadnavis on Saturday lauded an ambitious goal envisioned by experts in gestational diabetes: ensuring zero new cases of type 1 diabetes in India by 2047, the centenary of India's independence. Tired of too many ads? go ad free now Calling it a "revolutionary dream from Nagpur", Fadnavis said, "The goal set by diabetes experts to prevent new cases of Type 1 diabetes by 2047 is a bold and visionary one. Remarkably, this idea took root right here in Nagpur." Fadnavis was speaking while inaugurating the 12th edition of the Hello Diabetes Academia (HDA). The concept was explained by Dr Sunil Gupta, the organising chairman of the conference and a former national president of the Diabetes in Pregnancy Study Group of India (DIPSI). "If a woman maintains normal sugar levels before and during pregnancy, the risk of type 1 diabetes in the child can be significantly reduced. DIPSI is conducting awareness programmes in multiple Indian languages to educate women about the importance of sugar control even before conception. " He further said, "Our vision is to ensure that by the year 2047, India sees no new cases of type 1 diabetes, thanks to proactive maternal health education." Among the guests present at the event were Dr Rati Makkar, Padma Shri Dr Shashank Joshi, Padma Shri Dr Kamalakar Tripathi, Dr AK Das, Dr Banshi Saboo, Dr Vinky Rughwani and Dr Kavita Gupta, along with a host of national and international diabetes specialists and academicians. Speaking about the larger health crisis posed by diabetes and obesity, Fadnavis said, "Rapid urbanisation and the resulting unhealthy food habits are causing lifestyle diseases to emerge at younger ages. Tired of too many ads? go ad free now Such conferences play a vital role in creating awareness and empowering people to adopt healthier lifestyles." The CM highlighted the efforts of the 'Fit India Movement' launched by Prime Minister Narendra Modi. "Public awareness is the most powerful remedy against lifestyle diseases," he said. Fadnavis also appreciated the consistent efforts of Dr Sunil Gupta, saying, "He organised countless programmes across India, published research, and built platforms for awareness." The HDA 2025 conference features over 150 sessions, workshops and presentations on diabetes prevention, treatment strategies, endocrinology and lifestyle management. # DIPSI's road map - Promoting sugar control even before conception through pre-pregnancy counselling - Screening all pregnant women early for gestational diabetes using a simple single-test method - Educating mothers in all Indian languages about maintaining normal glucose levels during pregnancy - Organising awareness camps and workshops across rural and urban India - Preventing intergenerational transmission by targeting maternal blood sugar control